Perrigo Moves In On Major Generic Firms With Agis Acquisition
This article was originally published in The Tan Sheet
Executive Summary
Perrigo's acquisition of Israeli generic drug firm Agis Pharmaceuticals will put the combined entity's annualized sales over the $1 bil. mark and in the same league with major Rx generic drug players
You may also be interested in...
Perrigo appointment
Judy Brown, Senior VP and Corporate Controller for Perrigo, will assume her new role as the company's CFO and Chief Accounting Officer July 1, the Allegan, Mich.-based firm announces March 2. Brown will replace current CFO Douglas Schrank, who has been at Perrigo for six years. Brown is a certified public accountant who previously worked for Whirlpool and Ernst & Young. In her current role, Brown has helped lead the company through its acquisition of Agis Industries, which was completed in March (1"The Tan Sheet" Nov. 22, 2004, p. 6)...
Pseudoephedrine 2006 Sales To Decline 35%, Perrigo Projects
Perrigo's fiscal 2006 pseudoephedrine sales will decrease 35% to the $110 mil. to $120 mil. range, the company projected during a 2005 year-end and fourth quarter analysts call Sept. 7
Perrigo Predicts Cough/Cold Sales Drop Due To Pseudoephedrine BTC Move
Perrigo's cough/cold sales will likely be hurt in fiscal 2006 as retailers restrict pseudoephedrine products to behind-the-counter sale, according to the firm